Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, retrospective, real-world study of fingolimod in patients with relapsing remitting multiple sclerosis

Next Previous
X
Search
Trial Profile

A multicenter, retrospective, real-world study of fingolimod in patients with relapsing remitting multiple sclerosis

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms MS-MRIUS

    • Most Recent Events

    • 12 Dec 2017 Results assessing NEDA status in patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice, published in the CNS Drugs
    • 28 Oct 2017 Results of effects of fingolimod on brain atrophy presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Apr 2017 Results (n=571) assessing feasibility to measure brain atrophy presented at the 69th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top